id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1233-0007,FDA,FDA-2012-E-1233,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-03-12T04:00:00Z,2015,3,2015-03-12T04:00:00Z,,2015-03-12T12:51:03Z,,0,0,0900006481a3eaab
FDA-2012-E-1233-0006,FDA,FDA-2012-E-1233,"Determination of Regulatory Review Period for Purposes of Patent
Extension; Zuprevo",Notice,General Notice,2014-06-12T04:00:00Z,2014,6,2014-06-12T04:00:00Z,2014-08-12T03:59:59Z,2014-06-12T14:18:14Z,2014-13637,0,0,0900006481741115
FDA-2012-E-1233-0005,FDA,FDA-2012-E-1233,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-12T04:00:00Z,2014,5,2014-05-12T04:00:00Z,,2014-05-12T16:10:27Z,,0,0,09000064816f0f3a
FDA-2012-E-1233-0004,FDA,FDA-2012-E-1233,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2014-04-01T04:00:00Z,2014,4,2014-04-01T04:00:00Z,,2014-04-01T13:56:32Z,,0,0,0900006481694d64
FDA-2012-E-1233-0003,FDA,FDA-2012-E-1233,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2013-02-21T05:00:00Z,2013,2,2013-02-21T05:00:00Z,,2024-03-15T11:03:36Z,,0,0,090000648120100b
FDA-2012-E-1233-0002,FDA,FDA-2012-E-1233,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-28T00:24:28Z,,0,0,090000648119ceef
FDA-2012-E-1233-0001,FDA,FDA-2012-E-1233,"Toshiaki Miyake, et al (Wenderoth, Lind & Ponack LLP) - Patent Extension Application",Other,Application,2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-28T00:24:28Z,,0,0,090000648119ceed